Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T

被引:89
|
作者
Choi, I-Y [1 ]
Lee, S-P
Denney, D. R. [2 ]
Lynch, S. G.
机构
[1] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Dept Neurol,Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA
[2] Univ Kansas, Dept Psychol, Lawrence, KS 66045 USA
关键词
chemical shift imaging; glutathione; human brain; in vivo; magnetic resonance; neurodegeneration; oxidative stress; secondary progressive multiple sclerosis; IN-VIVO; OXIDATIVE STRESS; NEURODEGENERATIVE DISORDERS; WHITE-MATTER; DISEASE; PATHOGENESIS; METABOLISM; DISABILITY; CREATINE; SYSTEM;
D O I
10.1177/1352458510384010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Disability levels for patients with secondary progressive multiple sclerosis (SPMS) often worsen despite a stable MRI T-2 lesion burden. The presence of oxidative stress in the absence of measurable inflammation could help explain this phenomenon. In this study, the assessment of an in vivo marker of oxidative stress, cerebral glutathione (GSH), using magnetic resonance chemical shift imaging (CSI) is described, and GSH levels were compared in patients with SPMS and healthy controls. Objective: To assess whether GSH, a key antioxidant in the brain, is lower in the SPMS patients compared to matched controls. Methods: Seventeen patients with SPMS (Expanded Disability Status Scale = 4.0-7.0; length of MS diagnosis 19.4 +/- 7 years) and 17 age- and gender-matched healthy controls were studied. GSH levels were measured in the fronto-parietal regions of the brain using a specially designed magnetic resonance spectroscopy technique, CSI of GSH, at 3T. Results: The levels of GSH were lower for SPMS patients than for controls, the largest reduction (18.5%) being in the frontal region (p=0.001). Conclusion: The lower GSH levels in these patients indicate the presence of oxidative stress in SPMS. This process could be at least partially responsible for ongoing functional decline in SPMS.
引用
收藏
页码:289 / 296
页数:8
相关论文
共 50 条
  • [41] Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
    Schneider, Ruth
    Bellenberg, Barbara
    Hoepner, Robert
    Kolb, Eva-Maria
    Ellrichmann, Gisa
    Haghikia, Aiden
    Gold, Ralf
    Lukas, Carsten
    PLOS ONE, 2017, 12 (04):
  • [42] Three-dimensional J-resolved H-1 magnetic resonance spectroscopic Imaging of volunteers and patients with brain tumors at 3T
    Li, Yan
    Chen, Albert P.
    Crane, Jason C.
    Chang, Susan M.
    Vigneron, Daniel B.
    Nelson, Sarah J.
    MAGNETIC RESONANCE IN MEDICINE, 2007, 58 (05) : 886 - 892
  • [43] Magnetic resonance imaging results from the first year of the ADVANCE study, a pivotal phase 3 trial of peginterferon β-1a in patients with relapsing-remitting multiple sclerosis
    Arnold, D.
    Calabresi, P.
    Kieseier, B.
    Zhu, Y.
    Liu, S.
    Hung, S.
    Deykin, A.
    Sheikh, S.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 452 - 453
  • [44] 2D 1H sLASER Long-TE and 3D 31P Chemical Shift Imaging at 3 T for Monitoring Fasting-Induced Changes in Brain Tumor Tissue
    Alcicek, Seyma
    Dive, Iris
    Thomas, Dennis C.
    Prinz, Vincent
    Forster, Marie-Therese
    Czabanka, Marcus
    Weber, Katharina J.
    Steinbach, Joachim P.
    Ronellenfitsch, Michael W.
    Hattingen, Elke
    Pilatus, Ulrich
    Wenger, Katharina J.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2025, 61 (01) : 426 - 438
  • [45] Enkorten administration and its effects on gadolinium enhanced T1 and PD/T2 magnetic resonance imaging (MRI) lesions in patients suffering from relapsing-remitting multiple sclerosis (RRMS)
    Merhemic, Z.
    Mehmedika-Suljic, E.
    Alajbegovic, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S114 - S115
  • [46] The effects of interferons and copaxone on MMP-9/TIMP-1 ratio and TIMP-2 levels and on new enhancing lesions on magnetic resonance imaging in patients with relapsing-remitting multiple sclerosis
    Oztekin, Nese S.
    Oztekin, Fevzi M.
    Orhan, Guerdal
    Ak, Fikri
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S171 - S171
  • [47] Editorial for "2D 1H sLASER Long-TE and 3D 31P Chemical Shift Imaging at 3T for Monitoring Fasting-Induced Changes in Brain Tumor Tissue"
    Barker, Peter B.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2025, 61 (01) : 439 - 440
  • [48] Role of magnetic resonance spectroscopic imaging ([1H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA)
    Panebianco, V.
    Sciarra, A.
    Ciccariello, M.
    Lisi, D.
    Bernardo, S.
    Cattarino, S.
    Gentile, V.
    Passariello, R.
    RADIOLOGIA MEDICA, 2010, 115 (08): : 1314 - 1329
  • [49] ASPIRE (Azathioprine Secondary Progressive Interferon treated patients Randomised Evaluation) study: 2-year double-blind and 1-year open, randomised, multicentre, pilot study. Multiple Sclerosis Functional Composite (MSFC) and magnetic resonance data
    Montanari, E.
    Manneschi, L.
    Pesci, I.
    Motti, L.
    Merelli, E.
    Tola, M. R.
    Caputo, D.
    Provinciali, L.
    Scarpini, E.
    Marrosu, M. G.
    Ghezzi, A.
    Cavalla, P.
    Durelli, L.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S250 - S250
  • [50] Response of magnetic resonance T2 lesion load in patients with multiple sclerosis:: Blinded study of treatment with interferon-β1b (Betaseron) versus interferon-α-n-3 (Alferon n) versus untreated patients
    Onufer, J
    Whiteman, M
    Minagar, A
    Quencer, R
    Sheremata, WA
    ANNALS OF NEUROLOGY, 2001, 50 (03) : S28 - S28